News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharmaceuticals, Inc. and Abbott Laboratories (ABT) Announce Launch of AMITIZA in Japan


11/26/2012 11:16:12 AM

BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Abbott (NYSE: ABT) today announced the availability of AMITIZA® (lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases. AMITIZA was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in June. “Millions of patients in Japan have been suffering from chronic constipation, without efficacious and well-tolerated, long-term treatment options. We are pleased to bring AMITIZA’s experience of six years and over six million prescriptions in the United States to the Japanese market, to benefit the healthcare providers and patients who need it,” says Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and Chief Executive Officer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES